ABSTRACT
INTRODUCTION
The Chronic Kidney Disease (CKD) is characterized as a clinical condition wherein the progressive loss of renal function for a period longer than months to years will lead to the onset of end-stage renal disease (ESRD).
(1)
The CKD and ESRD have become a major public health problem worldwide, with a consequent increase in morbimortality and costs for the treatment of these diseases. In the United States, there are approximately 19 million adults with CKD and it is estimated that by the year 2030 more than two million people will require replacement therapy, dialysis or renal transplantation. (2) In the advanced stages of CKD, patients can only be treated with replacement therapy, dialysis or transplantation. In this context, hemodialysis (HD) presents as the main treatment option for these patients due to the lack of donors. Approximately 65% of ESRD patients perform HD, 25% undergo renal transplantation and 10% are treated with peritoneal dialysis. (3) In several countries of Europe, a high prevalence is also observed. In Germany, the prevalence of HD patients in 2009 was approximately 808 cases per million inhabitants. were more than 90.000 patients undergoing renal replacement therapy. (5) Patients with ESRD in HD often present signs and symptoms related to pre-existing or acquired comorbidities with worsening of the disease. The most frequent are electrolytic disturbances, anemia, malnutrition, bone disease, diabetes Melittus (DM) (6) , systemic arterial hypertension (SAH) (7, 8) ; gastrointestinal disorders; respiratory disorders (9) ; cardiovascular diseases (10) (11) (12) ; neurological changes (13) ; and sleep disorders. (14) The prevalence of sleep disturbances in ESRD in HD is considerable. Approximately 50-80% of these patients have sleep complaints, including insomnia, sleep apnea (central and / or obstructive), restless legs syndrome and excessive daytime sleepiness (ESD). (15) (16) (17) (18) The obstructive sleep apnea (OSA) presents a tenfold prevalence in patients with ESRD when compared to the general population, worsening the clinical symptoms and cardiovascular complications of this disease. 19 OSA is a serious clinical pathological condition characterized by repeated episodes of absence of airflow caused by total collapse of the upper airway for at least 10 seconds in the presence of ventilatory effort during sleep, usually accompanied by snoring, nocturnal hypoxemia and EDS. (20) Some studies have shown that OSA is more common in pathologies characterized by edemas, such as heart failure and renal failure. (21) (22) (23) One of the causes is due to the redistribution of intravascular and interstitial fluid from the lower limbs to the thoracic and cervical region, increasing the extraluminal pressure in the upper airway when patients assume the position of decubitus, especially when they go to sleep. Therefore, it has been shown that the displacement of rostral fluid during sleep contributes to the pathogenesis of OSA. (24) (25) (26) (27) The increase in the number of ESRD patients submitted to HD has assumed epidemic proportions worldwide. The negative impact on the quality of life and morbimortality caused by cardiorespiratory dysfunctions and sleep disorders is already well established in the literature. The causal association between sleep-disordered breathing, in particular OSA and ESRD, is still not well understood, which expands the possibility of new findings for the prevention, diagnosis and treatment of OSA, improving quality of life and reducing morbimortality.
Aims and Hypotheses
The present study involving ESRD patients undergone HD was designed with three main objectives: 1) to verify the prevalence and severity of sleep-disordered breathing; 2) to analyze the behavior of sleep apnea / hypopnea index (AHI) during the interdialitic period; 3) to verify weight gain and anthropometric measurements during the interdialitic period. According to the existing literature, we can hypothesize that AHI will vary during the interdialytic period in ESRD patients. (24) (25) (26) (27) 
METHODS

Study design and setting
A consecutive single-center cross-sectional clinical study will be performed, double-blind, non-randomized to investigate the behavior of AHI in patients with ESRD undergoing HD in the nephrology unit (UNEFRO) at the Hospital of Santa Casa de Misericordia de Avaré, (SP), Brazil. The design and conduct of this study followed the guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement, according to figure 1.
Participants
The subjects, patients diagnosed with ESRD undergoing regular HD, between 07:00 and 17:00h, 3 times a week, will be invited to participate in the study, consecutively and selected for eligibility in accordance with the proposed criteria. Inclusion criteria are patients of both sexes, aged between 18 and 70 years, candidates for renal transplantation, with sufficient cognitive level to understand the procedures and follow the instructions of the free and informed consent term. Will be excluded patients with craniofacial abnormalities, undergoing active treatment of OSA, had an left ventricle ejection fraction of ≤ 45% on routine echocardiography, active malignant disease, abusive use of alcohol and / or illicit drugs, dementia or treatment of psychiatric illnesses leading to an inability to provide informed consent.
Variables
Primary outcome
Variation of AHI during the interdialytic period in ESRD patients.
Secondary outcome
Prevalence and severity of sleep-disordered breathing in ESRD patients submitted to HD.
Ethical considerations
The study complied with the Declaration of 
Renal Replacement Therapy
Hemodialysis
Regular daytime HD will be standardised during the trial. It was performed 3 times per week, with a 4h session duration, 250mL/min blood flow, and 500mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C, and Polyflux 17L dialyser. The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, during the trial, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium channel blockers, and β blockers. The patients who required a change in medication for medical reasons were subsequently excluded from the study. Use of N acetylcysteine was also prohibited in view of its potential influence on ischemia reperfusion injury. (28) 
Study Protocol
Initially, patients underwent a medical consultation with anamnestic deepening to identify the complaints of sleep disorders and anthropometric evaluation. The clinical variables, such as comorbidities, dialysis time and renal disease etiology, and biochemical analysis of blood will be obtained from patients records. All subjects involved in this study should be clinically stable for at least three months.
Clinical Evaluation
The clinical evaluation will be performed by a doctor and a physiotherapist, including clinical history, check waist circumference and neck. For the calculation of body mass index (BMI) by weight / height 2 . The body weight (kg) and height (cm) will be verified through an electronic scale (model 200/5, Welmy Indústria e Comércio Ltda, São Paulo, Brazil) (29) Cardiac and respiratory rates and peripheral blood pressure will also be checked.
Waist and neck circumferences
The measurement of the circumferences will be performed with the patients in orthostatic position, using a non-elastic tape measure, with precision of 0.1cm and 7mm of width, parallel to the ground. The anatomical points for the measurements will be standardized. The waist circumference will be measured at the midpoint between the lower edge of the last rib and the iliac crest and the circumference of the neck will be checked horizontally on the cricoid cartilage. (30) 
Sleep Evaluation
Nocturnal Polygraphy
Nocturnal Home Polygraphy (PG) will be performed on the night after HD and on two subsequent nights using an type 3 portable monitoring Apnea Link Air device (ResMed Corporation, San Diego, CA, USA) including a five record signals of respiratory effort, respiratory flow, snore, blood oxygen saturation and pulse. (31) All respiratory events were manually scored by the same experienced pulmonologist, specialist in Sleep Medicine, according to the American Academy of Sleep Medicine criteria. The AHI will be calculated as the number of apneas and hypopneas per hour of recording, and OSA diagnosis was retained for AHI ≥ 5/h. (32) 
Quality control
To ensure data quality, all health professionals involved in this study will receive specific training. A periodic external monitoring will be performed to verify the adequate development of the proposed protocol.
Sample Calculation
Sample size was calculated according to a previously published clinical study (33) where the physiological sleep variables were analyzed in 20 patients with ESRD before and after HD through PSG, with a prevalence of 85% of OSA being observed using a cutt off > 15 AHI. The sample power test was calculated in 19 ESRD patients, adopting a 95% level of significance, with an error α of 5% and a error β = 90% (power test).
Statistical analysis
Statistical analysis will be conducted using SPSS version 22 (IBM, Chicago, IL, EUA). The Shapiro-Wilk test will be performed to verify the normality of the data. Mean and SD will be used to describe continuous variables, and percentages were used to describe categorical variables. Will be used a paired t test or McNemar test to compare the measurements performed before and after hemodialysis. Associations between continuous variables will be assessed by linear regression. Will be conducted univariate linear regressions to explore the factors associated with the severity of OSA. To further investigate the association between OSA and fluid overload, we will also compare the characteristics of participants in whom hemodialysis effectively reduced fluid overload in a post hoc analysis or chi-squared and t tests. Statistical significance will be establish at p value 0.05.
Description of risks
There will be no risks for included patients.
